Status: Not yet recruiting
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Serum Institute of India Pvt. Ltd.Updated: Jul 10, 2026Locations: 1
Eligibility criteria
Healthy Volunteers aged between 18 to 60 years inclusive. [+4]
History of Polio [+8]